多发性骨髓瘤
免疫疗法
癌症研究
骨髓
NK-92
白细胞介素12
淋巴因子激活杀伤细胞
免疫学
白细胞介素21
免疫系统
细胞疗法
医学
先天免疫系统
细胞
生物
细胞毒性T细胞
体外
T细胞
生物化学
遗传学
出处
期刊:PubMed
日期:2024-02-01
卷期号:32 (1): 297-301
标识
DOI:10.19746/j.cnki.issn.1009-2137.2024.01.048
摘要
Multiple myeloma (MM) is a hematologic neoplasm characterized by malignant proliferation of monoclonal plasma cells in the bone marrow. NK cells, a class of innate lymphocytes with potent natural killer activity, are capable of recognizing and destroying tumor cells and virally infected cells, and have attracted attention as a potential anticancer therapy. In patients with MM, NK cells are suppressed in number and function, resulting in reduced immune surveillance and clearance of myeloma cells. Restoring or enhancing the killing effect of NK cells on myeloma cells is an important strategy for MM immunotherapy, and some progress has been made in clinical trials targeting NK cellrelated therapies. This article reviews the research progress on the applications prospects of NK cell in MM immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI